<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275065</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-141-1219</org_study_id>
    <nct_id>NCT02275065</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects</brief_title>
  <official_title>A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the short-term antiviral potency, safety, plasma pharmacokinetics
      (PK), and the PK/pharmacodynamic (PD) relationship (the dose-response relationship) of
      GS-9883 at multiple doses in antiretroviral (ART) treatment-naive adult subjects and subjects
      who are ART-experienced but are currently off of ART therapy. Up to 32 participants will be
      enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAVG11 in plasma HIV-1 RNA (log10 copies/mL)</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>DAVG11: time-weighted average between the first postbaseline value and the last available value up to Day 11 minus the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and graded laboratory abnormalities</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>Overall safety profile will be characterized by number of participants experiencing adverse events or laboratory abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum reduction from baseline through Day 11 in plasma HIV-1 RNA (log10 copies/mL)</measure>
    <time_frame>Up to 11 Days</time_frame>
    <description>The maximum reduction will be calculated as the lowest up to Day 11 postbaseline value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of GS-9883 following single- and multiple-dose administration, and the correlation between AUCtau of GS-9883 and DAVG11 in plasma HIV-1 RNA</measure>
    <time_frame>Predose and postdose on Days 1 and 10</time_frame>
    <description>DAVG11: time-weighted average between the first postbaseline value and the last available value up to Day 11 minus the baseline value.
AUCtau: concentration of drug over time
PK measurements will include: AUCinf, AUC0-last, and Cmax for single-dose administration; and AUCtau, Cmax, and Ctau for multiple-dose administration.
PK/PD measurements will include Pearson correlation between AUCtau of GS-9883 and DAVG11 in plasma HIV-1 RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial viral decay slope in plasma HIV-1 RNA (copies/mL)</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>The ratio of the mean slopes between treatment pairs of interest will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9883 1 × 25 mg tablet (or placebo to match) for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9883 1 × 100 mg (or placebo to match) for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9883 5 mg or 10 mg (1 × 5 or 2 × 5 mg tablet) (or placebo to match) for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9883 50 mg or 75 mg (2 × 25 or 3 × 25 mg tablet) (or placebo to match) for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9883</intervention_name>
    <description>GS-9883 tablet(s) administered orally once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9883 Placebo</intervention_name>
    <description>Placebo to match GS-9883 administered orally once daily</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No current or prior anti-HIV treatment, including antiretroviral medications received
             for prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP)
             within 12 weeks of screening

          -  Must be between 18 and 65 years of age, inclusive on the date of the screening visit

          -  Plasma HIV-1 RNA ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening

          -  CD4+ cell count &gt; 200 cells/mm^3

        Exclusion Criteria:

          -  Anticipated to start HIV-1 therapy during the study period

          -  Active participation in another study of investigational or approved antiretroviral
             agents

          -  A new AIDS-defining condition diagnosed within the 30 days prior to screening

          -  Subjects with positive hepatitis C antibody at screening

          -  Chronic hepatitis B virus (HBV) infection

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hal Martin</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davis</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 Infected</keyword>
  <keyword>Adults</keyword>
  <keyword>Treatment Naive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

